Wyniki wyszukiwania - Biblioteka Nauki

Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na https://bibliotekanauki.pl

Ograniczanie wyników

Znaleziono wyników: 3

Liczba wyników na stronie

Wyniki wyszukiwania

Sortuj według:

Ogranicz wyniki do:

Metabolic activation in probably for cytotoxic activity of sesquiterpene lactones

100%

Kaminska M. , Niepsuj A. , Piesik J. , Jodynis-Liebert J. , Murias M.

tom 53

nr Supplement 1

AVE 0991 - angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE - knockout mice

72%

Toton-Zuranska J. , Gajda M. , Pyka-Fosciak G. , Kus K. , Pawlowska M. , Niepsuj A. , Wolkow P. , Olszanecki R. , Jawien J. , Korbut R.

tom 61

nr 2

Recent evidence shows that the renin-angiotensin system is a crucial player in atherosclerotic processes. It was also proved that Ang II promotes atherogenesis. Angiotensin-(1-7) [Ang-(1-7)] opposites Ang II action. Therefore, we would like to find out whether Ang-(1-7) receptor agonist: AVE 0991, could ameliorate atherosclerosis progression in an experimental model of atherosclerosis: apolipoprotein E (apoE) - knockout mice. AVE 0991 inhibited atherogenesis, measured both by “en face” method (7.63±1.6% vs. 14.6±2.1%) and “cross-section” method (47 235±7 546 µm2 vs. 91 416±8 357 µm2). This is the first report showing the effect of AVE 0991 on atherogenesis in gene-targeted mice.

The effect of nebivolol on atherogenesis in apoE - knockout mice

58%

Kus K. , Gajda M. , Pyka-Fosciak G. , Toton-Zuranska J. , Pawlowska M. , Suski M. , Niepsuj A. , Nowak B. , Wolkow P. , Olszanecki R. , Jawien J. , Korbut R.

nr 4

163-165

Nebivolol is a novel beta1-blocker with a nitric oxide (NO) - potentiating, vasodilatory effect that is unique among beta-blockers. It was already shown that nebivolol ameliorates atherosclerosis in cholesterol-fed rabbits. We, therefore, wanted to investigate whether this is the case in the fine experimental model of atherosclerosis: apolipoprotein E (apoE)- knockout mice. Nebivolol attenuated atherogenesis, measured both by "en face" method (9.23±1.8% vs. 14.6±2.1%) and "cross-section" method (63125±8455 µm2 vs. 91416±8357 m2). This is the first report showing the effect of nebivolol on atherogenesis in gene-targeted mice.